Mal-PEG8-Phe-Lys-PAB-Exatecan (TFA)

Mal-PEG8-Phe-Lys-PAB-Exatecan (TFA)

• UNSPSC Description: Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a agent-linker conjugate for ADC, composed of degradable linker Mal-PEG8-Phe-Lys-PAB and toxin molecule Exatecan (HY-13631)[1].
• Target Antigen: Drug-Linker Conjugates for ADC; Topoisomerase
• Type: Reference compound
• Related Pathways: Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/mal-peg8-phe-lys-pab-exatecan-tfa.html
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: O=C(C=CC1=O)N1CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCC(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CCCCN)C(NC(C=C3)=CC=C3COC(N[C@@H]4C5=C6C(C(N7C6)=CC([C@](O)(C(OC8)=O)CC)=C8C7=O)=NC9=CC(F)=C(C)C(CC4)=C95)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O
• Molecular Weight: 1548.58
• References & Citations: [1]Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1. |[2]Manel KRAIEM. Treatment of cancer. Patent WO2021151984A1.
• Shipping Conditions: Blue Ice
• Clinical Information: No Development Reported